Immunotherapies for locally aggressive cancers.
Autor: | Adams SC; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA., Nambiar AK; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA., Bressler EM; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA., Raut CP; Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA., Colson YL; Massachusetts General Hospital, Department of Surgery, Boston, MA 02114, USA. Electronic address: ycolson@mgh.harvard.edu., Wong WW; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA. Electronic address: wilwong@bu.edu., Grinstaff MW; Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA; Department of Chemistry, Boston University, Boston MA 02215, USA. Electronic address: mgrin@bu.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Advanced drug delivery reviews [Adv Drug Deliv Rev] 2024 Jul; Vol. 210, pp. 115331. Date of Electronic Publication: 2024 May 08. |
DOI: | 10.1016/j.addr.2024.115331 |
Abstrakt: | Improving surgical resection outcomes for locally aggressive tumors is key to inducing durable locoregional disease control and preventing progression to metastatic disease. Macroscopically complete resection of the tumor is the standard of care for many cancers, including breast, ovarian, lung, sarcoma, and mesothelioma. Advancements in cancer diagnostics are increasing the number of surgically eligible cases through early detection. Thus, a unique opportunity arises to improve patient outcomes with decreased recurrence rates via intraoperative delivery treatments using local drug delivery strategies after the tumor has been resected. Of the current systemic treatments (e.g., chemotherapy, targeted therapies, and immunotherapies), immunotherapies are the latest approach to offer significant benefits. Intraoperative strategies benefit from direct access to the tumor microenvironment which improves drug uptake to the tumor and simultaneously minimizes the risk of drug entering healthy tissues thereby resulting in fewer or less toxic adverse events. We review the current state of immunotherapy development and discuss the opportunities that intraoperative treatment provides. We conclude by summarizing progress in current research, identifying areas for exploration, and discussing future prospects in sustained remission. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |